Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA‐AF registry

BACKGROUND: Until the approval of dabigatran etexilate, treatment choices for stroke prevention in patients with atrial fibrillation (AF) were vitamin K antagonists (VKAs) or antiplatelet drugs. This analysis explored whether availability of non‐vitamin K antagonist oral anticoagulants post‐dabigatr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Changsheng, Riou França, Lionel, Lu, Shihai, Diener, Hans‐Christoph, Dubner, Sergio J., Halperin, Jonathan L., Li, Qiang, Paquette, Miney, Teutsch, Christine, Huisman, Menno V., Lip, Gregory Y. H., Rothman, Kenneth J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279964/
https://www.ncbi.nlm.nih.gov/pubmed/32528565
http://dx.doi.org/10.1002/joa3.12321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279964/
https://www.ncbi.nlm.nih.gov/pubmed/32528565
http://dx.doi.org/10.1002/joa3.12321

Ejemplares similares